First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma

Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation, showed signs of clinical efficacy in patients with basal cell carcinoma, according to results from a phase II clinical trial published in Clinical Cancer Research.